Tango Therapeutics delivers the next generation of precision medicine to people with cancer that leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer.
TNGX
3.78 as of 3/27/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 8/17/2020 | Series B-1 | $305.79MM | $XXX.XX | $XXX.XX |
| 4/9/2020 | Series B | $170MM | $XXX.XX | $XXX.XX |
| 3/30/2017 | Series A | $70.89MM | $XXX.XX | $XXX.XX |
